E3 PreliminaryPreliminaryPEM unclearMechanisticPeer-reviewedReviewed
Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Cabanas, Hélène, Muraki, Katsuhiko, Eaton, Natalie et al. · Molecular medicine (Cambridge, Mass.) · 2018 · DOI
Quick Summary
This study examined a specific ion channel called TRPM3 in immune cells called natural killer (NK) cells, which help fight infections and cancer. Researchers found that this channel doesn't work properly in ME/CFS patients compared to healthy people, which may affect how these immune cells function. This discovery could help explain why ME/CFS patients often have weakened immune responses.
Why It Matters
Understanding the specific molecular defects in NK cell function is crucial for ME/CFS because these cells are central to immune defense. This work provides a mechanistic basis for the previously documented reduced NK cell activity in ME/CFS, potentially opening avenues for targeted therapeutic interventions. Identifying functional ion channel abnormalities may help develop biomarkers for disease diagnosis and monitoring.
Observed Findings
- Significantly reduced TRPM3 current amplitude in patient NK cells after pregnenolone sulfate stimulation compared to healthy controls.
- Impaired modulation of pregnenolone sulfate-evoked currents by ononetin in ME/CFS NK cells versus control cells.
- Previous findings of reduced TRPM3 surface expression and decreased intracellular calcium mobilization in patient NK cells were supported by functional data.
- Differences were observed in whole-cell patch-clamp recordings between the two groups, indicating altered ion channel biophysics.
Inferred Conclusions
- TRPM3 ion channel function is impaired in NK cells from ME/CFS patients, suggesting disrupted calcium signaling.
- The dysfunction of TRPM3 may compromise NK cell cytotoxic capacity and contribute to reduced immune surveillance in ME/CFS.
- TRPM3 ion channels represent a potential molecular mechanism in the pathophysiology of ME/CFS.
- The observed channel dysfunction supports investigating TRPM3 as a target for therapeutic intervention in ME/CFS.
Remaining Questions
- Does TRPM3 dysfunction directly cause reduced NK cell killing capacity, or are other calcium signaling pathways also involved?
- Are TRPM3 mutations causative for ME/CFS or secondary consequences of chronic illness?
What This Study Does Not Prove
This study demonstrates that TRPM3 function is impaired in ME/CFS patients but does not prove this dysfunction causes the disease—it may be a consequence of illness rather than a cause. The small sample size (12 per group) and single-cell recording methodology limit generalizability. The study does not establish whether TRPM3 dysfunction alone explains the immune abnormalities observed in ME/CFS or whether other compensatory mechanisms are involved.
Tags
Symptom:Fatigue
Biomarker:Blood BiomarkerGene Expression
Method Flag:Small SampleExploratory OnlyWeak Case Definition
Metadata
- DOI
- 10.1186/s10020-018-0046-1
- PMID
- 30134818
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.